The use of emoxipin for correction of cyclophosphamide cytotoxicity in experimental animals.

In experiments on animals with Lewis lung carcinoma, emoxipin decreased hematotoxicity of cyclophosphamide without reducing its antitumor efficiency (effect on primary tumor node). Combined administration of emoxipin and cyclophosphamide more effectively prevented the development of metastases compared to cytostatic monotherapy.